


Claims:

1. A compound of the general formula I



5

wherein

X is O, S or CR¹¹R¹², wherein R¹¹ and R¹² independently are selected from H or C₁₋₆

10 alkyl;

Y is O or S;

R¹, R², R³ and R⁴ are independently selected from hydrogen; halogen; cyano; nitro; 15 C₁₋₆-alk(en/yn)yl; C₁₋₆-alk(en/yn)yloxy; C₁₋₆-alk(en/yn)ylsulfanyl; hydroxy; hydroxy-C₁₋₆-alk(en/yn)yl; halo-C₁₋₆-alk(en/yn)yl; halo-C₁₋₆-alk(en/yn)yloxy; C₃₋₈-cycloalk(en)yl; C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; acyl; C₁₋₆-alk(en/yn)yloxycarbonyl; C₁₋₆-alk(en/yn)ylsulfonyl; aryl optionally substituted with a 20 halogen, cyano, nitro, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yloxy, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(en/yn)yloxycarbonyl or C₁₋₆-alk(en/yn)ylsulfonyl; monocyclic 25 heteroaryl optionally substituted with a halogen, cyano, nitro, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yloxy, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(en/yn)yloxycarbonyl or C₁₋₆-alk(en/yn)ylsulfonyl; or -NR¹³R¹⁴ wherein R¹³ and R¹⁴ independently are selected from hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆ alk(en/yn)yl or aryl, or R¹³

and R¹⁴ together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N;

R⁵ is aryl or monocyclic heteroaryl, optionally substituted with a halogen, cyano, 5 nitro, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, hydroxy, hydroxy-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yl, halo-C₁₋₆-alk(en/yn)yloxy, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, acyl, C₁₋₆-alk(en/yn)yloxycarbonyl, C₁₋₆-alk(en/yn)ylsulfonyl or -NR¹⁵R¹⁶ wherein R¹⁵ and R¹⁶ independently are selected from hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₁₀ 10 -cycloalk(en)yl-C₁₋₆ alk(en/yn)yl or aryl, or R¹⁵ and R¹⁶ together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S or N;

R⁶ is selected from H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is selected from 15 C₁₋₆-alk(en/yn)yloxy, or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² independently are selected from H or C₁₋₆ alkyl;

R⁷ and R⁸ are independently selected from H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; 20 R⁹ and R^{9'} are independently selected from H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁶ and R⁸ together with the nitrogen form a saturated 3-7 membered heterocyclic ring, 25 and R⁷ is selected from H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R⁹ and R^{9'} are independently selected from H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁷ and R⁸ together with the nitrogen form a saturated 3-7 membered heterocyclic ring, 30 and R⁶ is selected from H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is selected from C₁₋₆-alk(en/yn)yloxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and R¹² independently are selected from H or C₁₋₆ alkyl, and R⁹ and R^{9'} are independently

selected from H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl; or

R⁸ and R⁹ together with the nitrogen form a saturated 3-7 membered heterocyclic ring,
5 and R⁶ is selected from H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is selected from
C₁₋₆-alk(en/yn)yloxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and
R¹² independently are selected from H or C₁₋₆ alkyl, and R⁷ is selected from H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R⁹ is selected from H, C₁₋₆-alk(en/yn)yl,
10 hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl;

R¹⁰ is H, C₁₋₆-alk(en/yn)yl, aryl, aryl-C₁₋₆-alk(en/yn)yl, wherein aryl is optionally
15 substituted with a halogen, CF₃, OCF₃, CN, NO₂ or C₁₋₆-alk(en/yn)yl; or an alkali metal;
or a salt thereof, such as a pharmaceutically acceptable salt.

2. The compound of claim 1 wherein X is selected from O or CH₂.

20 3. The compound of any one of claims 1-2 wherein Y is O.

4. The compound of any one of claims 1-2 wherein Y is S.

5. The compound of any one of the preceding claims wherein R¹ is selected from
25 hydrogen, C₁₋₆-alkyl, halogen, phenyl, or phenyl substituted with one or two substituents selected from C₁₋₆-alkyl or C₁₋₆-alkoxy.

6. The compound of any one of the preceding claims wherein R² is selected from
hydrogen; cyano; C₁₋₆-alkyl; halogen; phenyl; phenyl substituted with one or two
30 substituents selected from cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, or C₁₋₆-alkylsulfonyl; -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together with the nitrogen form a 3-7-membered heterocyclic ring which optionally contains one further heteroatom selected from O, S

or N, such as morpholinyl, or piperidinyl; or monocyclic heteroaryl, such as pyrimidinyl.

7. The compound of any one of the preceding claims wherein R³ is selected from
5 hydrogen; C₁₋₆-alkyl; halogen; phenyl; phenyl substituted with one or two substituents selected from cyano, C₁₋₆-alkyl, or C₁₋₆-alkoxy; or monocyclic heteroaryl, such as thiophenyl.

8. The compound of any one of the preceding claims wherein R⁴ is selected from
10 hydrogen, C₁₋₆-alkyl, halogen, phenyl or phenyl substituted with one or two substituents selected from C₁₋₆-alkyl or C₁₋₆-alkoxy.

9. The compound of any one of the preceding claims wherein R⁵ is phenyl,
optionally substituted with a halogen, C₁₋₆-alkyl, C₁₋₆-alkyloxy, C₁₋₆-alkylsulfanyl,
15 halo-C₁₋₆-alkyl.

10. The compound of any one of the preceding claims wherein R⁶ is selected from H or C₁₋₆-alkyl.

20 11. The compound of any one of the preceding claims wherein R⁷ is selected from H or C₁₋₆-alkyl.

12. The compound of any one of the preceding claims wherein R⁸ is selected from H, C₁₋₆-alkyl or C₃₋₈-cycloalkyl.

25 13. The compound of any one of the preceding claims wherein R⁹ and R^{9'} are independently selected from H or C₁₋₆-alkyl.

14. The compound of any one of the preceding claims wherein R¹⁰ is H.

30 15. The compound of any one of claims 1-9 or 14 wherein R⁶ and R⁸ together with the nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with a C₁₋₆-alkyl, and R⁷ is selected from H, C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and

R⁹ and R^{9'} are independently selected from H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl.

16. The compound of any one of claims 1-9 or 14 wherein R⁷ and R⁸ together with the

5 nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with
a C₁₋₆-alkyl, and R⁶ is selected from H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-
alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is selected from
C₁₋₆-alk(en/yn)yloxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and
R¹² independently are selected from H or C₁₋₆ alkyl, and R⁹ and R^{9'} are independently
10 selected from H, C₁₋₆-alk(en/yn)yl, hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆
alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-cycloalk(en)yl.

17. The compound of any one of claims 1-9 or 14 wherein R⁸ and R⁹ together with the

15 nitrogen form a 1-pyrrolidinyl, 1-piperidinyl or 1-azepinyl, optionally substituted with
a C₁₋₆-alkyl, and R⁶ is selected from H, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-
alk(en/yn)ylsulfanyl or C₃₋₈-cycloalk(en)yl, provided that when R⁶ is selected from
C₁₋₆-alk(en/yn)yloxy or C₁₋₆-alk(en/yn)ylsulfanyl then X is CR¹¹R¹², wherein R¹¹ and
R¹² independently are selected from H or C₁₋₆ alkyl, and R⁷ is selected from H, C₁₋₆-
alk(en/yn)yl or C₃₋₈-cycloalk(en)yl, and R^{9'} is selected from H, C₁₋₆-alk(en/yn)yl,
20 hydroxy-C₁₋₆-alk(en/yn)yl, C₁₋₆ alk(en/yn)ylsulfanyl-C₁₋₆-alk(en/yn)yl or C₃₋₈-
cycloalk(en)yl.

18. The compound of claim 1 selected from

(S)-1-{2-[2-(4-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

25 (S)-1-{2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic
acid,

(S)-1-{2-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-
carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic
30 acid,

(S)-{2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic
acid,

- (S)-1-{2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 5 (S)-1-{2-[2-(3-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Chloro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(4-Methoxy-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[2-(3,4-Difluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 10 1-{2(R/S)-[2-(4-Chloro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3,4-Difluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- (S)-1-{2-[2-(3-Fluoro-phenoxy)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 1-{2(R/S)-[2-(3-Fluoro-phenoxy)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 15 1-{2(R/S)-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- 1-{2(R/S)-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-pyrrolidine-2(S)-carboxylic acid,
- ({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
- 20 2-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
- {2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N--methyl-amino)-acetic acid,
- {2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- 25 {2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
- {2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,
- {4-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,
- (N-2-propyl-{2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
- 30 ({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,
- (N-Ethyl-{2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,
- 2-{3-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,
- (S)-{3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

(N-2-propyl- {2-[2-(4-methylsulfanyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

5 {3-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-ethyl-amino)-acetic acid,

({2-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{4-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,

2-{3-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic

10 acid,

({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-2-propyl-amino)-acetic acid

({2-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

{2-[2-(4-Methylsulfanyl-phenylsulfanyl)-phenoxy]-piperidin-1-yl}-acetic acid,

({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-ethyl}-N-methyl-amino)-acetic acid,

15 (N-Methyl- {2-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-ethyl}-amino)-acetic acid,

2-{3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-{3(R)-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-[3(R)-(2-(4-methylphenyl)-sulfanyl-phenoxy)-pyrrolidin-1-yl]-propionic acid,

20 {3(R)-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-acetic acid,

2-{3(R)-[2-(4-Trifluoromethyl-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

2-{3(R)-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-pyrrolidin-1-yl}-propionic acid,

25 ({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propyl}-N-ethyl-amino)-acetic acid,

({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-butan-3-methyl-2-yl}-N-ethyl-amino)-acetic acid,

30 ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[1-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-4-methyl-2-yl})-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]propan-2-yl}-N-ethyl-amino)-acetic acid,

5 (S)-{1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl }-N-methyl-amino)-acetic acid ,

(S)-({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl)-N-ethyl-amino)-acetic acid,

10 ({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-ethyl-amino)-acetic acid,

({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy[methyl]-propyl}-N-methyl-amino)-acetic acid,

15 ({1-[2-(4-Chloro-phenylsulfanyl)-phenoxy[methyl]-propyl}-N-ethyl-amino)-acetic acid,

(N-Ethyl-{1-[2-(3-fluoro-phenylsulfanyl)-phenoxy[methyl]-propyl}-amino)-acetic acid,

(R)-({2-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-1-methyl-ethyl}-N-ethyl-amino)-acetic acid,

20 (S)-(2{2-[2-(4-Chloro-phenoxy)-phenoxy]-propyl-N-methyl-amino)-acetic acid,

(R)-(2{2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-} -propyl-N-methyl-amino)-acetic acid,

({2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,

({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1yl}-N-ethyl-amino)-acetic acid,

25 ({1-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl-amino)-acetic acid,

({3-methyl-1-[2-(4-trifluoromethyl-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-ethyl-amino)-acetic acid,

30 ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-butan-2-yl}-N-methyl-amino)-acetic acid,

(S)-(1 {2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-2-yl} N-methyl-amino)-acetic acid,

- (S)-(2-{2-[2-(3-Fluoro-phenylsulfanyl)-phenoxy]-propyl}-N-methyl-amino)-acetic acid,
- ({1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-ethyl-amino)-acetic acid,
- 5 (S)-({1-[2-(3,4-Dichloro-phenylsulfanyl)-phenoxy]-propan-2-yl}-N-methyl-amino)-acetic acid,
- ({1-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-3-methyl-butan-2-yl}-N-methyl-amino)-acetic acid,
- ({1-[2-(4-tert-Butyl-phenylsulfanyl)-phenoxy]-3-methyl-propan-2-yl}-N-ethyl-amino)-acetic acid,
- 10 ({2-[2-(3-Chloro-4-fluoro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-ethyl-amino)-acetic acid,
- ({2-[2-(4-methoxy-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-Cyclohexyl-amino)-acetic acid,
- 15 { [2-(2-(4-methylsulfanyl-phenoxy)-propan-1-yl]-N-cyclohexyl-amino}-acetic acid,
- ({2-[2-(3-Chloro-phenylsulfanyl)-phenoxy]-propan-1-yl}-N-cyclohexyl-amino)-acetic acid,
- (S)-1-{3-[2-(3-Fluoro-phenylsulfanyl)-phenyl]-propyl}-pyrrolidine-2-carboxylic acid,
- (S)-2-({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-
- 20 propionic acid,
- ({2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-methyl-amino)-acetic acid,
- (S)-1-{2-[4-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,
- 25 (S)-1-{2-[3-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[5-Chloro-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[4-Cyano-2-(3-fluoro-phenylsulfanyl)-phenoxy]-ethyl}-pyrrolidine-2-
- 30 carboxylic acid
- (S)-1-[2-(5-Chloro-2-phenylsulfanyl-phenoxy)-ethyl]pyrrolidine-2-carboxylic acid,
- (S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Methoxy-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-{2-[4'-Cyano-3-(3-fluoro-phenylsulfanyl)-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

5 (S)-1-{2-[4'-Cyano-4-(3-fluoro-phenylsulfanyl)-biphenyl-3-yloxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-5-thiophen-3-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-pyrimidin-5-yl-phenoxy]-ethyl}-pyrrolidine-10 2-carboxylic acid,

(S)-1-{2-[3-(3-Fluoro-phenylsulfanyl)-3-methanesulfonyl-biphenyl-4-yloxy]-ethyl}-pyrrolidine-2(S)-carboxylic acid,

(S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-morpholin-4-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

15 (S)-1-{2-[2-(3-Fluoro-phenylsulfanyl)-4-piperidin-1-yl-phenoxy]-ethyl}-pyrrolidine-2-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising a compound according to any one of

20 claims 1-18 and a pharmaceutically acceptable carrier or diluent.

20. The use of a compound according to any one of claims 1-18 for the preparation of a medicament for the treatment of post-traumatic stress disorder or a disease selected from the group consisting of schizophrenia, including both the positive and the

25 negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive disorders such as epilepsy, spasticity or myoclonus.

30 21. A method for the treatment of a disease or disorder selected from the group consisting of post-traumatic stress disorder, the positive and the negative symptoms of

schizophrenia, including both the positive and the negative symptoms of schizophrenia and other psychoses, and in the improvement of cognition in conditions where the cognitive processes are diminished, i.e. Alzheimer's disease, multi-infarct dementia, AIDS dementia, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis or diseases wherein the brain is damaged by inner or outer influence, such as trauma to the head or stroke, and convulsive disorders such as epilepsy, spasticity or myoclonus in a living animal body, including a human, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1-18.